Research Papers:

Proteoglycan-targeting applied to hypoxia-activated prodrug therapy in chondrosarcoma: first proof-of-concept

Aurélien Voissiere _, Valérie Weber, Yvain Gerard, Françoise Rédini, Florian Raes, Jean-Michel Chezal, Françoise Degoul, Caroline Peyrode and Elisabeth Miot-Noirault

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:95824-95840. https://doi.org/10.18632/oncotarget.21337

Metrics: PDF 1452 views  |   HTML 2496 views  |   ?  


Aurélien Voissiere1, Valérie Weber1, Yvain Gerard1, Françoise Rédini2, Florian Raes3, Jean-Michel Chezal1, Françoise Degoul1, Caroline Peyrode1 and Elisabeth Miot-Noirault1

1Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Clermont-Ferrand, France

2Nantes Atlantique Université, INSERM, UMR1238, Sarcomes osseux et remodelage des tissus calcifiés, Nantes, France

3PHENOMIN-TAAM-UPS44, CIPA (Centre d’Imagerie du Petit Animal), CNRS Orléans, France

Correspondence to:

Aurélien Voissiere, email: [email protected]

Keywords: chondrosarcoma; proteoglycan; hypoxia-activated prodrug; quaternary ammonium; extracellular matrix

Received: January 26, 2017    Accepted: July 09, 2017    Published: September 27, 2017


Due to its abundant chondrogenic matrix and hypoxic tissue, chondrosarcoma is chemo- and radio-resistant. Our group has developed a proteoglycan targeting strategy by using a quaternary ammonium (QA) function as a carrier of DNA alkylating agents to chondrosarcoma environment. Here, we assessed the relevance of this strategy applied to hypoxia-activated prodrugs, by conjugating a QA to 2-nitroimidazole phosphoramidate. This derivative, named as 8-QA, was evaluated respectively to its non-QA equivalent and to a QA-conjugated but non-hypoxia activated. Firstly binding to aggrecan was confirmed from dissociation constant determined by Surface Plasmon Resonance. In vitro, in HEMC-SS chondrosarcoma cells cultured in monolayer and in spheroids, 8-QA showed higher cytotoxic activity in hypoxia versus normoxia, and led to a strong accumulation of cells in S phase and apoptosis. In vivo, a HEMC-SS xenograft model was implanted on SCID mice and characterized for hypoxia by photoacoustic imaging as well as proteoglycan content. When HEMC-SS bearing mice were given 8-QA at 47 μmol/kg according to a q4d x 6 schedule, a significant 62.1% inhibition of tumor growth was observed, without associated hematological side effects. Mechanistic studies of treated tumors highlighted decrease in mitotic index associated to increase in both p21 and p53S15 markers. Interestingly, 8-QA treatment induced an increase of DNA damages as measured by γH2AX predominantly found in pimonidazole-positive hypoxic areas. These preclinical results are the first to demonstrate the interest of addressing hypoxia-activated prodrugs selectively to proteoglycan of chondrogenic tumor tissue, as a promising therapeutic strategy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21337